Biochemical pharmacology of the lipophilic antifolate, trimetrexate
Authors:
- Robert C. JacksonRJRobert C. Jackson
- David W. FryDFDavid W. Fry
- Theodore J. BoritzkiTBTheodore J. Boritzki
- Judith A. BessererJBJudith A. Besserer
- Wilbur R. LeopoldWLWilbur R. Leopold
- Bernard J. SloanBSBernard J. Sloan
- Edward F. ElslagerEEEdward F. Elslager
- 1 January 1984
- journal article
- Published by Elsevier in Advances in Enzyme Regulation
- Vol. 22, 187-206
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediaminesJournal of Medicinal Chemistry, 1983
- The clinical pharmacology of methotrexateCancer Treatment Reviews, 1983
- Purification and characterization of dihydrofolate reductase from methotrexate-resistant human lymphoblastoid cellsBiochemistry, 1983
- 6 Recent Progress in the Medicinal Chemistry of 2,4-Diaminopyrimidines1982
- Enzymatic assays for 2, 4-diamino-5-methyl-6-[(3, 4, 5-trimethoxyanilino)methyl]quinazoline, a promising new “nonclassical” antifolateJournal of Pharmaceutical Sciences, 1981
- DDMP (2,4-diamino-5-(3′,4′-dichlorophenyl)-methylpyrimidine)Cancer Treatment Reviews, 1980
- Enzyme pattern-directed chemotherapyBiochemical Pharmacology, 1979
- Biochemical Mechanisms of Resistance to Antimetabolites1978
- Inhibition of mammalian dihydrofolate reductase by selected 2,4-diaminoquinazolines and related compoundsJournal of Medicinal Chemistry, 1974
- A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitorsBiochemical Journal, 1972